Outcome measures stratified for DAPSA, PASDAS, or ASDAS disease activity states in peripheral spondyloarthritis.
| DAPSA, n = 191 | PASDAS, n = 139 | ASDAS, n = 279 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAPSA Cut -offs | 1-way ANOVA | PASDAS Cut -offs | 1-way ANOVA | ASDAS Cut-offs | 1-way ANOVA | |||||||||||||
| Outcome Measure | ≤ 4, | 5 to ≤ 14, | 15 to ≤ 28, | ≥ 29, | F | P | ≤ 1.9, | 1.9 to < 3.2, | 3.2 to < 5.4, | ≥ 5.4, | F | P | < 1.3, | 1.3 to <2.1, | 2.1 to ≤ 3.5, | > 3.5, | F | P |
| n = 49 | n = 99 | n = 41 | n = 2 | n = 23 | n = 4 | n = 69 | n = 7 | n = 59 | n = 83 | n = 105 | n = 32 | |||||||
| (25.7%) | (51.8%) | (21.5%) | (1.0%) | (16.5%) | 0 (8.8%) | (49.6%) | (5.0%) | (21.1%) | (29.7%) | (37.6%) | (11.5%) | |||||||
| Disease activity | ||||||||||||||||||
| DAPSA (0-∞) | 2.1 (1.4) | 9.5 (2.9) | 18.9 (3.0) | 34.7 (7.8) | 346.6 | < 0.01 | 1.7 (1.9) | 5.5 (2.9) | 13.3 (5.2) | 22.1 (3.6) | 69.7 | < 0.01 | 3.2 (2.9) | 7.2 (4.8) | 12.9 (5.9) | 17.1 (3.8) | 50.2 | < 0.01 |
| PASDAS (0-∞) | 1.7 (0.9) | 3.4 (0.7) | 5.0 (0.6) | – | 132.6 | < 0.01 | 1.0 (0.5) | 2.7 (0.4) | 4.1 (0.6) | 5.9 (0.4) | 307.7 | < 0.01 | 1.8 (0.9) | 3.1 (1.0) | 4.2 (0.7) | 4.9 (0.6) | 64.2 | < 0.01 |
| ASDAS (0-∞) | 1.1 (0.5) | 2.2 (0.7) | 3.2 (0.8) | 3.2 (–) | 62.5 | < 0.01 | 0.9 (0.3) | 1.5 (0.6) | 2.7 (0.7) | 3.4 (0.8) | 64.7 | < 0.01 | 0.9 (0.3) | 1.7 (0.2) | 2.7 (0.4) | 3.9 (0.4) | 717.4 | < 0.01 |
| BASDAI (0–10) | 1.8 (1.6) | 4.6 (1.8) | 6.2 (1.9) | 7.6 (–) | 45.5 | < 0.01 | 1.0 (0.8) | 2.9 (1.7) | 5.4 (1.7) | 7.0 (1.7) | 54.1 | < 0.01 | 1.5 (0.9) | 3.2 (1.4) | 5.3 (1.6) | 7.0 (1.4) | 151.8 | < 0.01 |
| PtGA (0–10) | 1.0 (0.9) | 4.1 (1.8) | 7.2 (1.6) | 7.5 (0.7) | 117.0 | < 0.01 | 0.4 (0.7) | 2.2 (1.1) | 5.6 (1.8) | 8.3 (1.1) | 116.2 | < 0.01 | 1.1 (1.1) | 3.2 (1.8) | 5.2 (2.0) | 7.4 (1.4) | 119.0 | < 0.01 |
| VAS pain (0–10) | 0.7 (0.7) | 4.2 (1.9) | 6.7 (1.4) | 6.3 (1.0) | 119.6 | < 0.01 | 0.9 (1.9) | 2.6 (2.2) | 4.9 (1.8) | 7.4 (0.8) | 33.6 | < 0.01 | 1.6 (2.2) | 2.9 (2.0) | 5.3 (2.0) | 6.3 (1.4) | 56.2 | < 0.01 |
| PGA (0–10) | 0.8 (0.9) | 1.6 (1.0) | 3.2 (1.6) | 8.0 (–) | 34.7 | < 0.01 | 0.3 (0.6) | 1.4 (0.8) | 2.4 (1.0) | 5.6 (1.6) | 70.2 | < 0.01 | 1.0 (1.1) | 1.5 (1.2) | 2.3 (1.7) | 3.3 (1.8) | 14.5 | < 0.01 |
| CRP, mg/L (0-∞) | 2.3 (2.1) | 4.0 (4.2) | 7.5 (9.8) | 13.5 (16.3) | 8.3 | < 0.01 | 3.2 (2.9) | 2.4 (3.0) | 5.1 (6.8) | 5.6 (5.8) | 2.4 | 0.07 | 1.6 (1.1) | 2.5 (2.5) | 4.7 (5.6) | 15.2 (21.9) | 21.9 | < 0.01 |
| TJC68 (0–68) | 0.0 (0.3) | 0.6 (1.1) | 3.2 (2.4) | 15.5 (9.2) | 94.5 | < 0.01 | 0.0 (0.2) | 0.3 (0.6) | 1.7 (3.2) | 3.1 (1.7) | 6.5 | < 0.01 | 0.2 (0.5) | 0.8 (1.3) | 1.5 (3.1) | 1.9 (2.0) | 5.1 | < 0.01 |
| SJC66 (0–66) | 0.0 (0.3) | 0.3 (0.6) | 1.1 (1.3) | 4.0 (1.4) | 28.0 | < 0.01 | 0.0 (0.2) | 0.2 (0.4) | 0.4 (1.0) | 1.9 (1.9) | 9.2 | < 0.01 | 0.1 (0.4) | 0.4 (0.8) | 0.6 (1.4) | 0.6 (1.2) | 2.2 | 0.09 |
| LEI (0–6) | 0.0 (0.0) | 0.1 (0.3) | 0.2 (0.7) | 0.0 (–) | 1.3 | 0.29 | 0.1 (0.2) | 0.1 (0.2) | 0.0 (0.2) | 0.1 (0.4) | 0.9 | 0.44 | 0.0 (0.0) | 0.1 (0.3) | 0.1 (0.4) | 0.1 (0.3) | 1.6 | 0.18 |
| Dactylitis count (0–20) | 0.0 (0.0) | 0.0 (0.1) | 0.2 (0.6) | 0.0 (–) | 2.4 | 0.07 | 0.0 (0.0) | 0.0 (0.0) | 0.0 (0.4) | 0.1 (0.4) | 0.7 | 0.54 | 0.0 (0.3) | 0.0 (0.1) | 0.0 (0.3) | 0.1 (0.3) | 0.5 | 0.71 |
| Physical function and health impact | ||||||||||||||||||
| HAQ-S (0–3) | 0.2 (0.3) | 1.0 (0.6) | 1.2 (0.7) | 1.0 (–) | 19.3 | < 0.01 | 0.1 (0.2) | 0.5 (0.4) | 1.2 (0.6) | 2.0 (0.4) | 27.7 | < 0.01 | 0.2 (0.3) | 0.6 (0.6) | 1.1 (0.6) | 1.3 (0.6) | 30.1 | < 0.01 |
| ASAS HI (0–17) | 1.8 (1.7) | 6.0 (3.1) | 7.5 (3.3) | 11.0 (–) | 29.2 | < 0.01 | 1.5 (1.9) | 3.3 (2.2) | 7.1 (3.2) | 8.2 (3.3) | 28.1 | < 0.01 | 2.2 (1.7) | 4.3 (2.7) | 6.9 (3.4) | 8.3 (3.2) | 38.2 | < 0.01 |
| HRQOL | ||||||||||||||||||
| EQ-5D (0–1) | 0.94 (0.06) | 0.76 (0.12) | 0.64 (0.23) | 0.41 (–) | 25.7 | < 0.01 | 0.92 (0.13) | 0.85 (0.11) | 0.70 (0.23) | 0.87 (0.11) | 8.0 | < 0.01 | 0.93 (0.08) | 0.81 (0.14) | 0.71 (0.18) | 0.63 (0.24) | 22.9 | < 0.01 |
| SF-36 MCS (0–100) | 55.4 (7.1) | 47.6 (10.9) | 47.8 (11.4) | 22.1 (–) | 8.2 | < 0.01 | 54.3 (10.1) | 49.4(9.2) | 47.4 (11.4) | 50.8 (13.8) | 2.4 | 0.07 | 54.5 (7.4) | 51.9 (9.9) | 46.1 (11.1) | 44.9 (12.4) | 10.0 | < 0.01 |
| SF-36 PCS (0–100) | 49.7 (6.9) | 38.5 (8.9) | 32.1 (8.2) | 35.9 (–) | 31.2 | < 0.01 | 51.3 (7.5) | 46.8 (7.6) | 35.2 (7.3) | 24.5 (9.2) | 47.0 | < 0.01 | 49.1 (7.0) | 42.9 (8.9) | 35.4 (8.1) | 30.8 (5.0) | 47.9 | < 0.01 |
Values are presented as mean (SD) unless stated otherwise. ASAS HI: Assessment of SpondyloArthritis international Society Health Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; CRP: C-reactive protein; cDMARD: conventional disease-modifying antirheumatic drug; DAPSA: Disease Activity Index for Psoriatic Arthritis; EQ-5D: European Quality of Life 5 Dimensions; HAQ-S: Health Assessment Questionnaire for the Spondyloarthropathies; LEI: Leeds Enthesitis Index; MCS: Mental Component summary; NSAID: nonsteroidal antiinflammatory drugs; PASDAS: Psoriatic Arthritis Disease Activity Score; PCS: Physical Component summary; PGA: physician global assessment; PtGA: patient global assessment; SF-36: 36-item Short Form Health Survey; SJC66: swollen joint count in 66 joints; TJC68: tender joint count in 68 joints; VAS: visual analog scale.